摘要
目的探讨p16/Ki-67染色、HPV E6/E7mRNA和联合检测对HSIL+病变诊断的临床价值。方法募集2017年3月-2020年8月期间,于中山市博爱医院妇产科就诊,组织学证实为宫颈炎患者209例、LSIL患者169例、HSIL患者131例和宫颈癌患者86例作为研究对象,回顾分析研究对象术前细胞学样本p16/Ki-67染色、HPV E6/E7mRNA检测结果,纵向比较p16/Ki-67染色、HPV E6/E7mRNA和联合检测在不同级别宫颈病变的阳性率的差异,横向比较p16/Ki-67染色、HPV E6/E7mRNA和联合检测在相同宫颈病变的阳性率的差异,综合评估p16/Ki-67染色、HPV E6/E7mRNA和联合检测诊断HSIL+病变效能的差异。结果①纵向比较:p16/Ki-67染色、HPV E6/E7mRNA和联合检测阳性率随宫颈病变程度的加重呈趋势性升高(p16/Ki-67染色:χ^(2)=374.34,P<0.001;HPV E6/E7mRNA检测:χ^(2)=289.21,P<0.001;联合检测:χ^(2)=343.90,P<0.001)。②横向比较:在宫颈炎、LSIL、宫颈癌组,p16/Ki-67染色、HPV E6/E7mRNA和联合检测阳性率之间差异均不具有统计学意义(均P>0.05)。在HSIL组,p16/Ki-67染色和联合检测之间阳性率差异有统计学意义(χ^(2)=8.09,P=0.004);HPV E6/E7mRNA和联合检测之间阳性率差异有统计学意义(χ^(2)=11.30,P=0.001)。③p16/Ki-67染色、HPV E6/E-7mRNA和联合检测诊断HSIL+的灵敏度,总体差异有统计学意义(χ^(2)=7.69,P=0.021)。p16/Ki-67染色与联合检测法之间的灵敏度差异有统计学意义(χ^(2)=7.29,P=0.007);HPV E6/E7mRNA检测与联合检测法之间的灵敏度差异有统计学意义(χ^(2)=4.84,P=0.028)。p16/Ki-67染色、HPV E6/E7mRNA和联合检测诊断HSIL+的特异度及符合率的总体差异不具有统计学意义(χ^(2)_(1)=5.38,P1=0.068;χ^(2)_(2)=0.93,P2=0.628)。结论p16/Ki-67染色、HPV E6/E7mRNA和联合检测均可有效筛出HSIL+病变,但是联合检测能显著提高HSIL+病变诊断的灵敏度,降低漏诊率,同时保持了较好的特异度和符合率,建议将p16/Ki-67染色和HPV E6/E7mRNA联合检测作为早期诊断HSIL+病变的策略。
Objective To investigate the clinical value of p16/Ki-67 staining E6/E7 mRNA and combined detection in the diagnosis of HSIL+lesions.Methods From March 2017 to August 2020,209 cases of cervicitis,169 cases of LSIL,131 cases of HSIL and 86 cases of cervical cancer confirmed by histology were selected as the research objects.The results of p16/Ki-67 staining and HPV E6/E7 RNA detection of the preoperative cytological samples were retrospectively analyzed and the p16/Ki-67 staining and HPV E6/E7 mRNA detection results were compared longitudinally.The positive rates of E6/E7mRNA and combined detection in different grades of cervical lesions were compared.The positive rates of p16/Ki-67 staining,HPV E6/E7 mRNA and combined detection in the same cervical lesions were compared horizontally.The differences in the diagnostic efficacy of p16/Ki-67 staining,HPV E6/E7 mRNA and combined detection in the diagnosis of HSIL+lesions were comprehensively evaluated.Results①Longitudinal comparison:the positive rates of p16/Ki-67 staining,HPV E6/E7mRNA and combined detection increased with the severity of cervical lesions(p16/Ki-67 staining:χ^(2)=374.34,P<0.001;HPV E6/E7 mRNA detection:χ^(2)=289.21,P<0.001;joint detection:χ^(2)=343.90,P<0.001).②Transverse comparison:in cervicitis,LSIL and cervical cancer groups,there were no significant differences in the positive rates of p16/Ki-67 staining,HPV E6/E7 mRNA and combined detection(all P>0.05).In the HSIL group,there was significant difference in the positive rate between p16/Ki-67 staining and combined detection(χ^(2)=8.09,P=0.004)and the difference between HPV E6/E7 mRNA and combined detection was statistically significant(χ^(2)=11.30,P=0.001).③The sensitivity of p16/Ki-67staining,HPV E6/E7 mRNA and combined detection in the diagnosis of HSIL+was statistically significant(χ^(2)=7.69,P=0.021).The sensitivity difference between p16/Ki-67 staining and combined detection was statistically significant(χ^(2)=7.29,P=0.007);the sensitivity difference between HPV E6/E7 mRNA detection and combined detection method was statistically significant(χ^(2)=4.84,P=0.028).There was no significant difference in the specificity and coincidence rate of p16/Ki-67 staining,HPV E6/E7 mRNA and combined detection in the diagnosis of HSIL+(χ^(2)_(1)=5.38,P1=0.068;χ^(2)_(2)=0.93,P2=0.628).Conclusion P16/Ki-67 staining,HPV E6/E7 mRNA and combined detection may effectively screen out HSIL+lesions,reduce the missed diagnosis rate,but the combined detection may significantly improve the sensitivity of diagnosis of HSIL+lesions,while maintaining good specificity and coincidence rate.It is suggested that p16/Ki-67 staining and HPV E6/E7 mRNA detection should be used as a strategy for early diagnosis of HSIL+lesions.
作者
简凤萍
罗燕艳
梁锐根
徐秀梅
邓文同
JIAN Fengping;LUO Yanyan;LIANG Ruigen;XU Xiumei;DENG Wentong(Department of Obstetrics and Gynecology,Zhongshan BOAI Hospital,Zhongshan 528400,China;Department of Pathology,Zhongshan BOAI Hospital,Zhongshan 528400,China)
出处
《广州医药》
2021年第2期17-21,共5页
Guangzhou Medical Journal
基金
中山市社会公益科技研究专项立项(2019B1029)。